Glivec decision raises more questions about the Indian IP Office

The Indian IP Appeal Board's decision to reject a Novartis patent application relating to the Glivec anti-cancer treatment gets an extensive review on the Spicy IP blog. The board gives a number of reasons for the rejection, but one rings very…

Get unlimited access to all IAM content